Ticker Details
Kura Oncology, Inc. Kura Oncology Inc is a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers.
IPO Date:	September 16, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$998.71M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.38 | 2.82%
Avg Daily Range (30 D):	$0.22 | 2.36%
Avg Daily Range (90 D):	$0.21 | 2.39%

Institutional Daily Volume
Avg Daily Volume:	.56M
Avg Daily Volume (30 D):	1.4M
Avg Daily Volume (90 D):	1.29M

Trade Size
Avg Trade Size (Sh.):	91
Avg Trade Size (Sh.) (30 D):	85
Avg Trade Size (Sh.) (90 D):	83

Institutional Trades
Total Institutional Trades:	3,120
Avg Institutional Trade:	$1.83M
Avg Institutional Trade (30 D):	$1.53M
Avg Institutional Trade (90 D):	$1.56M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.97M
Avg Closing Trade (30 D):	$1.7M
Avg Closing Trade (90 D):	$1.73M
Avg Closing Volume:	137.48K

News

Apr 24, 2026 @ 12:00 PM Kyowa Kirin and Kura Oncology Initiate Japanese Ph... Source: Na

Apr 17, 2026 @ 10:00 AM Kura Oncology Reports Darlifarnib Plus Cabozantini... Source: Na

Apr 3, 2026 @ 11:30 AM Kura Oncology Reports Inducement Grants Under Nasd... Source: Na

Dec 4, 2025 @ 5:20 PM Blood Cancer Therapeutics Reach Critical Commercia... Source: Prnewswire

Nov 25, 2025 @ 10:16 PM KOMZIFTIâ„¢ (ziftomenib) Added to National Com... Source: Kura Oncology And Kyowa Kirin

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.83	$-.92	$-3.18
Diluted EPS	$-.83	$-.92	$-3.18
Revenue	$18.27M	$17.34M	$67.48M
Gross Profit	$18M
Net Income / Loss	$-73.33M	$-81M	$-278.67M
Operating Income / Loss	$-78.82M	$-86.27M	$-303.63M
Cost of Revenue	$.26M
Net Cash Flow	$-110.02M	$53.81M	$-75.36M
PE Ratio